Burkholderia cepacia infection in children without cystic fibrosis: a clinical analysis of 50 cases
Authors:
Open Access
- 15 May 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 11
Abstract
Background: Burkholderia cepacia (B. cepacia) is an emerging pathogen of nosocomial infection in pediatric patient carrying cystic fibrosis. The clinical diagnosis and treatment of B. cepacia infection remains poorly studied. This study outlined the risk factors, antimicrobial susceptibility, and clinical characteristics aiming to improve the treatment of B. cepacia infection.Methods: A retrospective study was conducted based on the 50 cases infection caused by B. cepacia in children without cystic fibrosis, which were diagnosed in the First Affiliated Hospital of Xiamen University, from January 1st, 2011 to December 31st, 2021.Results: A total of 50 children were infected with B. cepacia, of whom 68% had an underlying health condition, such as cardiovascular disease (23.5%), respiratory disease (17.6%), nervous system disease (14.7%), and neoplastic disease (14.7%). At the onset of B. cepacia infection, 42 (84%) pediatric patients were in an intensive care unit (ICU), 33 (66%) underwent endotracheal intubation, and 32 (64%) had a central venous catheter (CVC). In addition, hospital-acquired cases were 46 (92%), and healthcare-acquired cases were 4 (12%). The most common infectious sites of B. cepacia were the respiratory tract (68%), followed by the blood (20%), and the urinary tract (12%). It indicated that B. cepacia was the most sensitive to ceftazidime (95.65%), followed by trimethoprim-sulfamethoxazole (88.68%), meropenem (82.98%), cefepime (77.78%), and levofloxacin (55.85%). The drug resistance rate of piperacillin-tazobactam, minocycline, aztreonam, cefoperazone-sulbactam and ceftriaxone was higher than 55%. 38 cases were cured or improved, eight had treatment terminated, and four died.Conclusion: B. cepacia is an opportunistic pathogen normally found in immunocompromised pediatric patients and highly likely to lead to drug resistance. Nosocomial B. cepacia infections occurred mostly in patients in the ICU based on our observations. The surveillance of B. cepacia infections including changing epidemiology and increasing resistance of the microorganism is still very important. Treatment with effective antibiotics such as ceftazidime, meropenem, trimethoprim-sulfamethoxazole is associated with a favorable prognosis.Keywords
This publication has 24 references indexed in Scilit:
- Burkholderia Sepsis in Children as a Hospital-Acquired InfectionYonsei Medical Journal, 2016
- Burkholderia cepacia Sepsis Among NeonatesIndian Journal of Pediatrics, 2014
- Clinical characteristics and outcomes of patients with Burkholderia cepacia bacteremia in an intensive care unitDiagnostic Microbiology and Infectious Disease, 2011
- Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidenceInternational Journal of Antimicrobial Agents, 2009
- Two outbreaks of Burkholderia cepacia nosocomial infection in a neonatal intensive care unitJournal of Paediatrics and Child Health, 2007
- Risk Factors forBurkholderia cepaciaComplex Bacteremia Among Intensive Care Unit Patients Without Cystic Fibrosis: A Case-Control StudyInfection Control & Hospital Epidemiology, 2007
- Hemophagocytic Syndrome and Burkholderia cepacia Splenic Microabscesses in a Child With Chronic Granulomatous DiseaseThe Pediatric Infectious Disease Journal, 2004
- Virulence Associated with Outbreak-Related Strains of Burkholderia cepacia Complex among a Cohort of Patients with BacteremiaClinical Infectious Diseases, 2004
- Health Care–Associated Bloodstream Infections in Adults: A Reason To Change the Accepted Definition of Community-Acquired InfectionsAnnals of Internal Medicine, 2002